Advertisement

Pharmacy World and Science

, Volume 27, Issue 2, pp 92–95 | Cite as

Boron neutron capture therapy for glioblastoma multiforme

  • Catharina M. van. RijEmail author
  • Abraham J. Wilhelm
  • Wolfgang A. G. Sauerwein
  • Arie C. van. Loenen
Article

Abstract

Aim: Glioblastoma multiforme (GBM) is an incurable disease that can only be managed in a palliative way. The GBM accounts for approximately half of all newly diagnosed primary brain tumors with an incidence of 2–3 cases per 100,000 people each year. Surgery and radiation are the standard options for palliation, and whether there is a place for chemotherapy is still discussed. Boron neutron capture therapy (BNCT) is a promising and possibly curative method of treating GBM. The purpose of this article is to provide an updated review on the current management and future possibilities of treating GBM with BNCT.

Method: Use was made of computerized searches and of checking cross-references of articles and book chapters.

Results: The principle of BNCT uses the high ability of 10B to capture thermal neutrons and to disintegrate immediately into a He nucleus (α-particle) and a Li nucleus. To reach a sufficient concentration of 10B in the malignant cells compared to the surrounding healthy tissue, 10B-carriers must be highly tumor-selective. At present, the 10B carriers boronophenylalanine (BPA) and sodium borocaptate (BSH) are used in clinical trials to perform BNCT.

Conclusion: The BNCT is a promising and possibly curative method of treating GBM, but at present this procedure is far from perfect. Because of the lack of selectivity of the boron carriers, it appears so far that radiation toxicity limits the radiation dose, so that tumor damage is modest. Current investigations and developments are aimed at targeting the boron carriers to the tumor, in order to limit the damage to the healthy, surrounding tissue.

Keywords

BNCT Boron neutron capture therapy Boronophenylalanine Glioblastoma multiforme Sodium borocaptate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Sanden, GAC, Schouten, LJ., Dijck, JAAM,  et al. 1998Incidence of primary central nervous system cancers in south and east Netherlands in 1989–1994Neuroepidemiology.1724757CrossRefPubMedGoogle Scholar
  2. Hartog, T. 2001Biological Aspects of Biodistribution in BNCT, a literature reviewNRG PettenThe NetherlandsGoogle Scholar
  3. Hariharan S, Uddin ABMS, Glioblastoma Multiforme. Version April 4, 2002. http://www.emedicine.com/NEURO/topic 147.htmGoogle Scholar
  4. Archambeau, JO. 1970The effect of increasing exposures of the 10B(n,a)7Li-recation on the skin of manRadiology.9417887Google Scholar
  5. Gabel, D., Sauerwein, WAG 1995Approaching clinical trials of boron neutron capture therapy in EuropeKogelnik, HD eds. Progress in Radio-oncology V. BolognaModuzzi EditoreItaly315319Google Scholar
  6. Sauerwein, WAG. 1993Principles and history of neutron capture therapyStrahlenther Onkol.116Google Scholar
  7. Hideghéty, K., Sauerwein, WAG., Haselberger, K.,  et al. 1999Postoperative treatment of glioblastoma with BNCT at the Petten irradiation facility (EORTC protocol 11961)Strahlenther Onkol.1551114Google Scholar
  8. Sauerwein, WAG., Zurlo, A. 2002The EORTC boron neutron capture therapy (BNCT) group: achievements and future projectsEur J Cancer.38S314CrossRefGoogle Scholar
  9. Verbakel, WF., Sauerwein, WAG., Hideghety, K.,  et al. 2003Boron concentration in brain during boron neutron capture therapy: in vivo measurements from the phase I trial EORTC 11961 using a gamma-ray spectroscopeInt J Radiat Oncol Biol Phys.5574356CrossRefPubMedGoogle Scholar
  10. Hideghety, K., Sauerwein, WAG., Wittig, A.,  et al. 2003Tissue uptake of BSH in patients with Glioblastoma in the EORTC 11961 phase I BNCT trialJ Neuro Oncol.6214556CrossRefGoogle Scholar
  11. Paquis, P, Hideghety, K, Wittig, A,  et al. 2002Tissue uptake of BSH in patients with Glioblastomas in the EORTC 11961 phase I trialSauerwein, WAGMoss, RWittig, A eds. Research and Development in Neutron Capture TherapyMonduzzi EditoreBologna, Italy11171121Google Scholar
  12. Elowitz, EH., Bergland, RM., Coderre, JA.,  et al. 1998Biodistribution of p-boronophenylalanine in patients with Glioblastoma Multiforme for use in Boron Neutron Capture TherapyNeurosurgery.424638CrossRefPubMedGoogle Scholar
  13. Fukuda, H., Honda, C., Wadabayashi, N.,  et al. 1999Pharmacokinetics of 10B-p-boronophenylalanine in tomours, skin and blood of melanoma patients: a study of Boron Neutron Capture Therapy for malignant melanomaMelanoma Res.97583PubMedGoogle Scholar
  14. Coderre, JA., Chanana, AD., Joel, DD.,  et al. 1998Biodistribution of boronophenylalanine in patients with Glioblastoma Multiforme: boron concentration correlates with tumor cellularityRadiat Res.14916370PubMedGoogle Scholar
  15. Chadha, M., Capala, J., Coderre, JA.,  et al. 1998Boron Neutron Capture Therapy (BNCT) for Glioblastoma Multiforme (GBM) using the epithermal neutron beam at the Brookhaven National LaboratoryInt J Radiat Oncol Biol Phys.4082934CrossRefPubMedGoogle Scholar
  16. Chanana, AD., Capala, J., Chadha, M.,  et al. 1999Boron Neutron Capture Therapy for Glioblastoma Multiforme: interim results from the phase I/II dose-escalation studiesNeurosurgery.44118292CrossRefPubMedGoogle Scholar
  17. Busse PM., Harling OK., Palmer MR. et al. A phase I clinical trial for cranial BNCT at Harvard-MIT. Report 2001Google Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  • Catharina M. van. Rij
    • 1
    Email author
  • Abraham J. Wilhelm
    • 1
  • Wolfgang A. G. Sauerwein
    • 2
  • Arie C. van. Loenen
    • 1
  1. 1.Department of PharmacyVU’University Medical CenterAmsterdamThe Netherlands
  2. 2.Department of Radiation OncologyUniversity of Duisburg-EssenGermany

Personalised recommendations